Markets:

Overview

News

Currencies

International

Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.670 +0.150 (+3.32%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗

April 26, 2024

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...

Via Benzinga

Topics Intellectual Property Lawsuit

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

April 24, 2024

Via ACCESSWIRE

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

April 24, 2024

Via ACCESSWIRE

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

April 24, 2024

Via ACCESSWIRE

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

April 18, 2024

Via ACCESSWIRE

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

November 14, 2023

Via ACCESSWIRE

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

April 16, 2024

Via ACCESSWIRE

Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert ↗

April 12, 2024

Via Benzinga

CureVac, GS Partner Release Data On Influenza Vaccine Study ↗

April 04, 2024

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...

Via Benzinga

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

April 04, 2024

Via ACCESSWIRE

Why Biopharmaceutical Player CureVac Shares Are Rising Today ↗

January 05, 2024

CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.

Via Benzinga

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

January 05, 2024

Via ACCESSWIRE

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 19, 2023

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...

Via Benzinga

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? ↗

December 19, 2023

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of

Via Benzinga

Topics Intellectual Property Lawsuit

Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday ↗

December 19, 2023

U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company...

Via Benzinga

Topics Stocks

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

December 19, 2023

Via ACCESSWIRE

Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology ↗

November 15, 2023

Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...

Via Benzinga

Topics Intellectual Property Lawsuit

Earnings Scheduled For November 14, 2023 ↗

November 14, 2023

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.

Via Benzinga

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

November 01, 2023

Via ACCESSWIRE

Why CureVac Stock Plunged Today ↗

September 29, 2023

A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.

Via The Motley Fool

Topics Lawsuit

Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

September 28, 2023

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant...

Via Benzinga

3 Stocks to Buy For the COVID Resurgence

September 06, 2023

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

Via MarketBeat

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

August 17, 2023

Via ACCESSWIRE

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

August 01, 2023

Via ACCESSWIRE

CureVac Announces Update to the Management Team

July 14, 2023

Via ACCESSWIRE

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

July 13, 2023

Via ACCESSWIRE

Why Shares of CureVac Jumped This Week ↗

June 23, 2023

The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.

Via The Motley Fool

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

Why CureVac Stock Leaped 12% Higher Today ↗

June 20, 2023

The war on cancer advances with the German company's latest clinical development.

Via The Motley Fool

DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday ↗

June 20, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.